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ABSTRACT
Objectives: This study aims to estimate the prevalence of rheumatoid arthritis (RA) and spondyloarthritis (SpA) in Turkey using the same telephone 
questionnaire developed for screening RA and SpA in France and used in Serbia and Lithuania.
Material and methods: The study was performed in two steps. In step I, the French questionnaire was translated into Turkish and validated through 
a group of 200 patients (80 males, 120 females; mean age 44.0±13.1 years; range, 19 to 75 years) followed up at the rheumatology departments 
of University Hospitals in Antalya and Ankara. In step II, the validated Turkish questionnaire was administered face-to-face to randomly selected 
4,012 subjects (1,670 males, 2,342 females; mean age 41.5±16.8 years; range, 16 to 97 years) by trained general practitioners across the country, in 
25 provinces for case detection. The subjects who were suspected of having RA or SpA in accordance with the questionnaire were invited to the 
nearest university hospital for rheumatologic examination in order to confirm the diagnosis.
Results: In step II, a total of 25 subjects (2 males, 23 females) were diagnosed as RA. The standardized RA prevalence for the general population of 
Turkey was calculated as 0.56% (95% confidence interval [CI]; 0.33-0.79), 0.10% (95% CI; -0.05-0.25) for males and 0.89% (95% CI; 0.51-1.27) for females. 
A total of 18 subjects (3 males, 15 females) were diagnosed as SpA. The standardized SpA prevalence for the general population of Turkey was 0.46% 
(95% CI; 0.25-0.67), 0.17% (95% CI; -0.03-0.37) for males and 0.65% (95% CI; 0.32-0.98) for females. The prevalence of RA was highest in the Northern 
region (2.00%) and the prevalence of SpA was highest in the Central region (1.49%).
Conclusion: The prevalences of RA and SpA in Turkey are close to each other and there are significant inter-regional variations in prevalences of 
both RA and SpA.
Keywords: Epidemiology; prevalence; rheumatoid arthritis; spondyloarthritis.
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Rheumatoid arthritis (RA) and spondyloarthritis 
(SpA) are the most common inflammatory 
arthropathies in adults. RA is a systemic, 
autoimmune, inflammatory disease primarily 
affecting the peripheral synovial joints. Owing 
to progressive joint damage, it may result in 
functional impairment and disability. SpAs are a 
group of rheumatic diseases including ankylosing 
spondylitis (AS), psoriatic arthritis, reactive arthritis 
and enteropathic arthropathies. In developed 
countries, a large number of publications are 
available on the prevalence of RA and SpA.1,2 
However, in low- and middle-income countries, 
studies on RA and SpA are sparse. Likewise, in 
Turkey, epidemiological studies regarding RA and 
SpA reported to date are very few and regional, 
rather than nationwide.3-5
After a survey, a telephone questionnaire 
developed for screening RA and SpA was validated 
and used for several surveys in France.6-10 Given 
the French experience and the support of the 
European League Against Rheumatism (EULAR), 
it became possible to carry out similar studies 
across Europe using the same methodology. 
In this way, the aforementioned telephone 
questionnaire was adapted to and validated in 
Serbian and Lithuanian, and also used in a 
prevalence survey carried out in Lithuania11,12 
and Serbia.13 Our study was based on the same 
questionnaire and endorsed by EULAR and the 
Turkish League Against Rheumatism. To the 
best of our knowledge, this is the first nationwide 
epidemiological study to estimate the prevalence 
of RA and SpA in Turkey. Therefore, in this 
article, we aimed to estimate the prevalence of 
RA and SpA in Turkey using the same telephone 
questionnaire developed for screening RA and 
SpA in France and used in Serbia and Lithuania.
MATERIAL AND METHODS
This study was conducted in two steps: in the first 
step the aforementioned French questionnaire 
was translated into Turkish and validated 
through a group of patients followed up at the 
rheumatology departments of Akdeniz University 
Hospital (Antalya), and of Ankara University 
Hospital (Ankara). In step II, the validated Turkish 
version was used in a nationwide survey to detect 
the prevalence of RA and SpA in 25 provinces of 
Turkey. The study was conducted in accordance 
with the principles of the Declaration of Helsinki.
Step I
The original French questionnaire, which 
comprised 33 items covering signs, symptoms, 
self-reported diagnosis and classification criteria 
for RA (American College of Rheumatology 
[ACR] 1987)14 and SpA (The European 
Spondylarthropathy Study Group [ESSG] 
1991),15 was translated into Turkish using the 
standard methodology of forward then backward 
translations and expert committee decision 
making.16 200 patients were included in the study 
(80 males, 120 females; mean age 44.0±13.1 
years; range, 19 to 75 years). The questionnaire’s 
validity was tested by administering it to the 
subjects, divided into four groups: (i) patients 
with RA, (ii) patients with SpA, (iii) patients with 
diagnoses of non-inflammatory musculoskeletal 
diseases such as osteoarthritis, osteoporosis, 
fibromyalgia, disc herniation, spondylosis and 
non-specific mechanical low back pain, and 
(iv) controls. All patients were recruited from the 
hospital registries of Akdeniz University and of 
Ankara University, and controls were selected 
from the general population using randomly 
sampled telephone numbers. All patients with RA 
and SpA were also required to fulfill ACR 1987 
and ESSG 1991 classification criteria, respectively. 
Two certified rheumatologists and two physiatrists 
experienced in rheumatic diseases ascertained the 
patients’ clinical diagnoses and documented their 
findings on standard forms. All the subjects were 
interviewed by telephone by a trained layperson 
who was unaware of the patients’ diagnoses. 
Subjects who did not answer the telephone were 
reached by subsequent calls.
Step II
Turkey is a country divided into seven 
geographical regions (the Aegean [the Western], 
the Marmara [the Northwestern], the 
Mediterranean [the Southern], the Black Sea 
[the Northern], the Central, the Eastern, and the 
Southeastern) and 81 administrative provinces. 
Its population derived from the national census 
data was 67.8 million in 2000.17
In step I I, the validated Turkish 
questionnaire was administered face-to-
face to randomly selected 4,012 subjects 
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(1,670 males, 2,342 females; mean age 
41.5±16.8 years; range, 16 to 97 years) by 
20 trained general practitioners across the 
country for case detection. For randomization 
process, a two-stage cluster sampling method 
was used (Table 1). The first stage corresponded 
to all the seven geographical regions mentioned 
above and the second stage to 25 provinces: 
Adana, Afyon(karahisar), Ankara, Antalya, 
Aydın, Bursa, Denizli, Diyarbakır, Edirne, 
Elazı¤, Erzurum, Gaziantep, Isparta, ‹stanbul, 
‹zmir, Kayseri, Kırıkkale, Kocaeli, Konya, 
Malatya, Manisa, Mersin, Samsun, Sivas, and 
Van (Figure 1). Two levels of either urban 
or rural settlement type defined the second 
stage. Urban clusters were selected by the 
proportional sampling method using zip codes 
and the rural clusters were sampled from the 
lists of villages not further than 80 km from 
the relevant provincial city center. The number 
of clusters was determined in proportion to the 
size of the urban and rural population of the 
relevant province. For intra-cluster sampling, a 
quota sampling method was used to determine 
the appropriate number of subjects according 
to the age and sex. The interviewer chose any 
street from the sampled zip code by his own will 
and started the interviews beginning from the 
first block on the right side of the street in the 
urban settlements or beginning from the first 
house on the right side of the reeve’s office in 
the rural settlements until he/she completed the 
predetermined cluster size. Inclusion criteria for 
the study were as follows: being 16 years of age 
or over, giving oral consent to participate in the 
screening, and being a citizen of Turkey. All the 
subjects belonging to the household and present 
on site during the screening were interviewed, 
but those who were cognitively impaired or 
unable to understand the questions, or unable to 
give clear answers were excluded. Any present 
visitors not belonging to the household but 
belonging to the same cluster were included; 
otherwise, they were excluded.
The diagnostic procedure was carried out 
according to the algorithm suggested by the 
questionnaire itself. For case confirmation, the 
subjects who were suspected of having RA or SpA 
in accordance with the questionnaire were invited 
to the nearest university hospital to be examined 
by a rheumatologist or a physiatrist experienced 
in rheumatic diseases and, if needed, to undergo 
some laboratory and/or X-ray investigations to 
confirm the diagnosis.
Table 1. Procedure of sampling and randomization in 
step II
A. Sampling
Northwestern 810 220
Northern 240 250
Western 330 210
Central 480 210
Eastern 200 170
Southern 310 200
Southeastern 110 100
Adana 120 40
Afyon 30 40
Ankara 270 50
Antalya 80 80
Aydın 30 40
Bursa 110 50
Denizli 30 40
Diyarbakır 110 100
Edirne 20 20
Elazı¤ 40 30
Erzurum 60 50
Gaziantep 130 50
Isparta 30 20
‹stanbul 630 100
‹zmir 190 50
Kayseri 60 30
Kırıkkale 20 10
Kocaeli 50 50
Konya 100 90
Malatya 50 40
Manisa 50 40
Mersin 80 60
Samsun 240 250
Sivas 30 30
Van 50 50
B. Randomization
1. Randomizing the  urban settlements from the list of zip code 
and rural settlements from the list of villages not further than 
80 km from the provincial center.
2. Performing the interviews beginning  from the first block 
located on the right side of the selected any street by the 
interviewer belonging to the randomized zip code in the 
urban settlements and beginning from the first house on the 
right side of the reeve’s house in the rural settlements.
3. Terminating the interviews when the number of performed 
interviews reached the predetermined cluster size (10-20) for 
that zip code or village.
* Numbers were rounded to the nearest ten.
1. First stage: Determining of urban and rural sample sizes for 
all seven geographical regions
 Sample size* (n)
Region Urban Rural
2. Second stage: Determining of urban and rural sample sizes 
for selected 25 provinces
 Sample size* (n)
Region Urban Rural
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Statistical analysis
Step I
The sensitivity and specificity were calculated 
for each item of the questionnaire, separately 
and in combination, in reference to the clinical 
diagnosis and the classification criteria. Statistical 
analysis for step I was performed using SAS® 8.0 
statistical software.
Step II
We found that at least 3,984 individuals needed 
to be included in our study, for an estimated 
prevalence of 0.03 and precision level of 0.01, 
corrected by a 1.6-fold increase for the impact 
of design at an a error level of 0.05. Using the 
direct standardization method, the prevalence 
estimates were adjusted for age and sex to Turkey’s 
population based on the data obtained in the 2000 
Turkish national census. The 95% confidence 
intervals (CIs) were calculated as suggested.18 Odds 
ratios and 95% CIs for regional variation of 
standardized prevalence estimates were obtained 
using MedCalc® statistical software version 17.6 
(MedCalc Software bvba, Ostend, Belgium).
RESULTS
Of a total of 200 subjects recruited in step I, 
52 (6 males, 46 females) had RA, 49 (42 males, 
7 females) had SpA, 49 (11 males, 38 females) 
had non-inflammatory musculoskeletal diseases, 
and 50 (21 males, 29 females) were controls. 
The mean age of patients with RA, SpA, 
non-inflammatory musculoskeletal diseases, and 
controls were 52.6±10.0, 39.6±10.8, 49.7±10.0 
and 34.2±12.4 years, respectively. All of the 
subjects were contacted by telephone and they 
responded to the questionnaire. When the clinical 
diagnosis was taken as the standard, sensitivity 
of the items on the questionnaire ranged from 
94% to 0% in RA, and from 90% to 2% in SpA 
(Table 2).
The distribution of the study sample and 
Turkey’s population by age and sex were shown 
in Table 3. In step II, a total of 25 subjects 
(2 males, 23 females) were diagnosed as RA 
(Table 4). The mean age of males and females 
with RA was 49.0±11.3 years (range, 41-57 
years) and 46.5±15.0 years (range, 20-70 years), 
respectively. The crude prevalence for RA was 
0.62% (95% CI; 0.38-0.86) in general, 0.12% 
(95% CI; -0.05-0.29) for males and 0.98% 
(95% CI; 0.58-1.38) for females.
The standardized RA prevalence for the 
general population of Turkey was calculated 
as 0.56% (95% CI; 0.33-0.79), 0.10% 
(95% CI; -0.05-0.25) for males and 0.89% 
(95% CI; 0.51-1.27) for females (Table 5). 
Figure 1. Regions of Turkey and provinces selected for the study.
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The highest prevalence of RA was in the age 
group of 55-64 years (1.11%) (Table 4). The 
prevalence of RA was highest in the Northern 
region (2.00%) indicating a significant regional 
difference (p=0.003, Table 6).
A total of 18 subjects (3 males, 15 females) 
were diagnosed as SpA (Table 4). The mean age 
was 38.0±11.4 years (range, 25-46 years) for 
males and 36.7±11.2 years (range, 23-62 years) 
for females. The crude weighted prevalence for 
Table 3. Age and sex distribution of study sample and Turkey’s population
 16-24 419 17.9 302 18.1 6093983 26.5 6382124 27.6
 25-34 546 23.3 355 21.3 5376110 23.4 5528800 23.9
 35-44 463 19.8 341 20.4 4386033 19.1 4537110 19.6
 45-54 374 16.0 273 16.3 3018970 13.1 3067148 13.3
 55-64 254 10.8 198 11.9 2007157 8.7 1880553 8.1
 65-74 209 8.9 132 7.9 1505409 6.5 1312751 5.7
 ≥75 77 3.3 69 4.1 603977 2.6 436812 1.9
 Total 2342 100.0 1670 100.0 22991639 100.0 23145298 100.0
 Study sample Turkey’s population
 Age (year) Female Male Female Male
  n % n % n % n %
Table 4. Distribution of cases by age group and sex
 16-24 1 0.14 - - 1 0.14 2 0.28 - - 2 0.28 721 100.00
 25-34 5 0.55 - - 5 0.55 6 0.67 1 0.11 7 0.78 901 100.00
 35-44 5 0.62 1 0.12 6 0.75 4 0.50 1 0.12 5 0.62 804 100.00
 45-54 5 0.77 - - 5 0.77 2 0.31 1 0.15 3 0.46 647 100.00
 55-64 4 0.88 1 0.22 5 1.11 1 0.22 - - 1 0.22 452 100.00
 65-74 3 0.88 - - 3 0.88 - - - - - - 341 100.00
 ≥75 - - - - - - - - - - - - 146 100.00
 Total 23 0.57 2 0.05 25 0.62 15 0.37 3 0.07 18 0.45 4012 100.00
 Cases with rheumatoid arthritis Cases with spondyloarthritis  Study sample
 Age (year) Female Male Total Female Male Total Total
  n % n % n % n % n % n % n %
Table 5. Standardized prevalence of rheumatoid arthritis and spondyloarthritis in overall population of Turkey 
aged 16 or over
Rheumatoid arthritis 0.56 0.33-0.79 0.89 0.51-1.27 0.10 -0.02-0.38
Spondyloarthritis 0.46 0.25-0.67 0.65 0.32-0.98 0.17 -0.03-0.37
CI: Confidence interval.
 Total (%) 95% CI Female 95% CI Male 95% CI
Table 6. Crude and standardized prevalence of rheumatoid arthritis in regions of Turkey
Northwestern 1,027 0.29 -0.04-0.62 0.25 -0.06-0.56 1.0 
Northern 490 2.04 0.79-3.29 2.00 0.76-3.24 7.1 1.9-26.0 0.003
Western 540 0.56 -0.07-1.19 0.53 -0.08-1.14 1.9 0.4-9.5 0.430
Central 689 0.87 0.18-1.56 0.72 0.09-1.35 2.5 0.6-10.5 0.212
Eastern 368 0.27 -0.26-0.80 0.32 -0.26-0.90 0.9 0.1-9.0 0.950
Southern 509 0.39 -0.15-0.93 0.31 -0.17-0.79 1.3 0.2-8.1 0.745
Southeastern 389 0 0 0 0 0.4 0.0-7.3 0.518
CI: Confidence interval; OR: Odds ratio.
Region Sample Crude Standardized
 n % 95% CI % 95% CI OR 95% CI p
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Table 7. Crude and standardized prevalence of spondyloarthritis in regions of Turkey
Northwestern 1,027 0.10 -0.09-0.29 0.18 -0.08-0.44 1.0 
Northern 490 0.61 -0.08-1.30 0.78 0.00-1.56 4.2 0.8-23.1 0.097
Western 540 0.37 -0.14-0.88 0.34 -0.15-0.83 1.9 0.3-13.6 0.520
Central 689 1.45 0.56-2.34 1.49 0.59-2.39 7.5 1.6-34.6 0.009
Eastern 368 0.54 -0.21-1.29 0.53 -0.21-1.27 2.8 0.4-20.0 0.304
Southern 509 0 0 0 0 0.4 0.0-8.4 0.557
Southeastern 389 0 0 0 0 1.0 0.8-23.1 0.679
CI: Confidence interval; OR: Odds ratio.
Region Sample Crude Standardized
 n % 95% CI % 95% CI OR 95% CI p
SpA was 0.45% (95% CI; 0.24-0.66) in general, 
0.18% (95% CI; -0.02-0.38) for males and 0.64% 
(95% CI; 0.32-0.96) for females.
The standardized SpA prevalence for the 
general population of Turkey was calculated 
as 0.46% (95% CI; 0.25-0.67), 0.17% 
(95% CI; -0.03-0.37) for males and 0.65% 
(95% CI; 0.32-0.98) for females (Table 5). The 
highest prevalence of SpA was in the age group 
of 25-34 years (0.78%) (Table 4). The prevalence 
of SpA was highest in the central region (1.49%) 
pointing to a significant regional difference 
(p=0.009) (Table 7).
DISCUSSION
To the best of our knowledge, this is the first 
nationwide survey showing the estimates of 
prevalence of RA and SpA in Turkey. Previous 
epidemiological studies on RA and SpA in Turkey 
were carried out in just one urban metropolitan 
area, i.e. Antalya4 or in a few urban quarters 
not representing the whole metropolitan area, 
i.e. ‹zmir3,5 or in a few regional small urban 
areas, i.e. the eastern Black Sea region19 or in 
an urban and rural area of a small town, i.e. 
Havsa.20 All of these studies were performed 
using face-to-face questionnaires. Of those, three 
used cluster sampling,3-5 one intended to reach 
the entire population living in the study area20 
and one did not mention how the sampling 
procedure was managed.19 Four of those studies 
were held mainly in coastal urban areas,3-5,19 not 
taking into consideration the hinterland and rural 
areas. Therefore, our study had the advantage 
of covering both urban and rural areas and also 
inland Turkey.
We used a questionnaire endorsed by EULAR, 
which was also used in France, Lithuania and 
Serbia,9,10,12,13 providing a reliable opportunity 
to compare the differences between countries. 
However, we used it in face-to-face interviews 
unlike the telephone interviews employed in 
France, Lithuania and Serbia, because neither 
the landline phones nor the mobile phones were 
in use in some rural areas of Turkey and landline 
phones where available in Turkey were largely 
being replaced by mobile phones at the time the 
survey was carried out. In doing so, we aimed to 
capture all the individuals intended to be involved 
in the study. Thus, despite being less costly than 
face-to-face surveys, telephone surveys might 
result in lower response rates.21
Our study indicates a prevalence of 0.56% for 
RA adjusted for the general population aged 16 
or over. In previous studies, the prevalence of RA 
adjusted for the general population aged 20 or 
over of Turkey was estimated as 0.32%, 0.36%, 
0.42% and 1.01% in Havsa, ‹zmir, Antalya and 
the eastern Black Sea region, respectively.3,4,19,20 
Those studies indicate that RA prevalence shows 
regional variations in Turkey. Indeed, our study 
has also shown that there are regional variations 
in the prevalence of RA. The prevalence of RA 
was highest in the Northern region (2.04%) and 
lowest in the Southeastern region (0%).
Our study showed a prevalence of 0.46% for 
SpA adjusted for the general population aged 
16 or over. As expected, prevalence of SpA was 
highest in the age group of 25-34 years (1.28%). 
The prevalence of SpA was also heterogeneous 
among regions as of RA, being significantly 
highest in the Central region (1.45%). Interregional 
variations in prevalence of SpA were also shown 
in previous studies.22-24 The prevalence of SpA 
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shows correlations with the prevalence of human 
leukocyte antigen B27 (HLA-B27).24 According 
to two small non-population based studies, -one 
from the West and the other from the East of 
Turkey- the frequency of HLA-B27 varies between 
2.8% and 11.1% in Turkey.25,26 This considerably 
broad range of HLA-B27 frequency suggests an 
apparent interregional variation in the prevalence 
of SpA. However, we are not sure whether the 
heterogeneity of regional prevalence of SpA in 
Turkey can be explained by HLA-B27 frequency, 
as no nationwide data exist on the prevalence of 
HLA-B27. At present, regarding the paucity of 
data, we cannot rule out the environmental risk 
factors for heterogeneity of the prevalence of SpA 
as well.
On the other hand, we found a higher 
prevalence of SpA in females compared to males 
(0.65% vs. 0.17%, respectively). Interestingly, in 
a previous regional prevalence study performed 
in Turkey, the prevalence of SpA was also higher 
in females than in males (1.22% vs. 0.88%, 
respectively).5 In that study, it was shown that 
the overall prevalence of SpA (1.05%) was even 
higher than of RA. A previous study conducted 
in Canada revealed that male/female prevalence 
ratio of AS decreased from 1.70 in 1995 to 1.21 
by 2010 and the prevalence of AS tripled over the 
past two decades.27 This suggests that both the 
prevalence of SpA and the proportion of female 
patients with SpA might be increasing in other 
parts of the world as well, which may be due to 
the increasing awareness of SpA in recent years.
We detected no case of RA or SpA in the 
Southeastern region. This could be partly explained 
by the region itself, containing one of the smallest 
populations in the survey. It is hard to establish a 
conclusion, since no prevalence study conducted 
in this region exists, which would support this 
result. Further regional studies using the same 
methodology related to the prevalence of RA and 
SpA are required to assist us in understanding the 
genetic and environmental factors.
Our study has some limitations. Face-to-face 
interviews might have their own limitations such 
as encountering more females than males in 
households, since the labor force is overwhelmingly 
comprised of males in Turkey, rendering the 
females mostly homemakers. Accordingly, 58% 
of the individuals involved in our study were 
females whereas the national census performed 
in 2000 showed that females constituted 50% 
of Turkey’s population. The rate of females was 
even higher (61%) in the Northern region where 
the prevalence of RA was highest. This could be a 
bias for the higher prevalence of RA as it is known 
that RA is mostly seen in females. However, in the 
Lithuanian study in which the same methodology 
(by telephone) was used, the authors emphasized 
the same problem.12 Another limitation of our 
study was not studying the HLA-B27.
In conclusion, our study showed that a north-
south gradient of RA across Europe might not 
exist, compared to the prevalence reported from 
Northern European countries.12,28 However, a 
north-south gradient of RA might exist in Turkey. 
Regarding SpA, the proportion of female patients 
may be higher than expected while there are 
interregional differences in the prevalence of SpA.
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